Retatrutide vs Tirzepatide: price and facts compared (2026)
Neither product has an in-stock offer right now.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Category | GLP-1 | GLP-1 |
| Standard size | 30mg | 30mg |
| All sizes | 10mg, 15mg, 20mg, 30mg, 50mg | 10mg, 20mg, 30mg, 40mg, 60mg |
| Cheapest now | Not in stock | Not in stock |
| Price per mg | Priced as a set | Priced as a set |
| Vendors | 0 | 0 |
| Forms | Vial | Vial |
| Regulatory status | Investigational · phase 3 (Eli Lilly). Not approved for human use. | FDA-approved as Mounjaro (2022) and Zepbound (2023). The research vial is not the approved product. |
| Stock | Out of stock | Out of stock |
Retatrutide is an investigational triple-agonist peptide acting on GLP-1, GIP and glucagon receptors, developed by Eli Lilly and studied in phase 3 obesity trials. Research vendors sell it as a lyophilized powder in 10–30 mg vials.
Retatrutide prices →Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide and the active compound in Mounjaro and Zepbound. Research-grade tirzepatide is sold lyophilized in 10–60 mg vials.
Tirzepatide prices →Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. Prices include a discount only when the offer shows a code, and exclude shipping. Stock status is captured at the same time. Rankings are by price only. PeptideTech earns a commission when you buy through a link; it never changes the order.
Full method →